A new study co-authored by the FVE and aquaculture experts highlights a persistent gap between the authorisation and availability of veterinary medicinal products for finfish in Europe. Published in Veterinary Sciences, the study covers the EU and EFTA countries from 2018 to 2026.
Authorisation does not mean availability
While the number of authorised products increased from 304 in 2018 to 332 in 2025, the number of authorised products with unique active substances that were available fell from 84 to 70. Current data indicate that only 26.5% of authorised products are actively marketed, creating what the authors describe as a “paper market” that conceals significant therapeutic gaps.
Limited options for key fish species
The authors note that the shortage is particularly evident in seabass, seabream, carp and trout production. Limited market size, industry consolidation, increased environmental requirements and growing administrative and financial burdens are identified as potential drivers. Despite mechanisms in EU veterinary medicines legislation intended to support limited markets, therapeutic diversity remains stagnant and aquaculture continues to rely heavily on off-label use, they add.
Access needed for sustainable growth
With demand for fish products increasing, the study argues that European aquaculture has an important role to play in strengthening EU self-sufficiency. Improved access to authorised medicinal products, particularly alternatives to antibiotics, is essential 'to prevent and treat disease while safeguarding fish health and welfare' and supporting sustainable sector growth.
Therapeutic challenges in the finfish sector were also identified at a stakeholder meeting in March.
(photo ©Bob Brewer/Unsplash)